Our efforts thus far indicated that anti-PD-L1 alone could affect tumor macrophage activation in vitro, yet our mouse tumor model was most responsive to checkpoint blockade when administered as a combination immunotherapy (Figure 1). The gene discussed is CD274; the disease is neoplasm.